{"id":"nivolumab-relatlimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":{"setId":"b22c9d83-3256-4e17-85f7-f331a504adc6","title":"OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) INJECTION [E.R. SQUIBB & SONS, L.L.C.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, preventing immune suppression. Relatlimab is a LAG-3 inhibitor that blocks LAG-3, another inhibitory checkpoint on T cells. Together, this dual checkpoint blockade removes multiple brakes on the immune system, allowing T cells to recognize and attack cancer cells more effectively.","oneSentence":"Nivolumab and relatlimab together block two immune checkpoints (PD-1 and LAG-3) to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:19.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (unresectable or metastatic)"},{"name":"Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":156},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT05987241","phase":"PHASE2, PHASE3","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-02","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma","enrollment":992},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":"Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer","enrollment":32},{"nctId":"NCT03521830","phase":"PHASE2","title":"Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-27","conditions":"Basal Cell Carcinoma","enrollment":57},{"nctId":"NCT05347212","phase":"PHASE2","title":"Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-22","conditions":"Carcinomas, Renal Medullary Carcinoma","enrollment":30},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT06708949","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-20","conditions":"Renal Cell Carcinoma, Clear Cell","enrollment":15},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT05176483","phase":"PHASE1","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2021-12-14","conditions":"Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)","enrollment":1314},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT07459543","phase":"PHASE4","title":"A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-11-15","conditions":"Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma","enrollment":30},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT06561386","phase":"PHASE3","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Non-small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT05255601","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-09-13","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease","enrollment":5},{"nctId":"NCT06112314","phase":"PHASE3","title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","status":"RECRUITING","sponsor":"Immunocore Ltd","startDate":"2024-06-05","conditions":"Advanced Melanoma","enrollment":680},{"nctId":"NCT06999980","phase":"PHASE2","title":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2026-02-09","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":494},{"nctId":"NCT06246916","phase":"PHASE3","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-09","conditions":"Melanoma","enrollment":560},{"nctId":"NCT06963905","phase":"PHASE1, PHASE2","title":"Saci Nivo Rela for TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-29","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT05912244","phase":"PHASE2","title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-09","conditions":"Melanoma","enrollment":43},{"nctId":"NCT06151236","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-03-11","conditions":"Merkel Cell Carcinoma","enrollment":20},{"nctId":"NCT04552223","phase":"PHASE2","title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","status":"COMPLETED","sponsor":"Jose Lutzky, MD","startDate":"2020-11-10","conditions":"Metastatic Uveal Melanoma","enrollment":27},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT06880549","phase":"PHASE1","title":"A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-03-25","conditions":"Advanced Solid Tumors","enrollment":57},{"nctId":"NCT06624475","phase":"PHASE2","title":"Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-08-21","conditions":"Basal Cell Carcinoma","enrollment":30},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT06697197","phase":"PHASE1, PHASE2","title":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-17","conditions":"Advanced Solid Tumors","enrollment":413},{"nctId":"NCT07369791","phase":"PHASE2","title":"Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.","status":"NOT_YET_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2026-05","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":76},{"nctId":"NCT06208657","phase":"PHASE1, PHASE2","title":"Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer","status":"RECRUITING","sponsor":"Australian & New Zealand Children's Haematology/Oncology Group","startDate":"2024-07-10","conditions":"Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor","enrollment":90},{"nctId":"NCT06715241","phase":"PHASE2","title":"A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS","status":"ACTIVE_NOT_RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2024-12-11","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":77},{"nctId":"NCT05704647","phase":"PHASE2","title":"Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-02-23","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT05337137","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-05","conditions":"Carcinoma, Hepatocellular","enrollment":83},{"nctId":"NCT06816927","phase":"PHASE2","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-28","conditions":"Newly Diagnosed Glioblastoma","enrollment":92},{"nctId":"NCT05002569","phase":"PHASE3","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-10-19","conditions":"Melanoma","enrollment":1093},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT04326257","phase":"PHASE2","title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","status":"COMPLETED","sponsor":"Dan Zandberg","startDate":"2020-05-14","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":20},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT04567615","phase":"PHASE2","title":"A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-02-04","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult","enrollment":266},{"nctId":"NCT01968109","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-11-05","conditions":"Neoplasms by Site","enrollment":1482},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":"Melanoma, Unresectable Melanoma","enrollment":105},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT04658147","phase":"PHASE1","title":"Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-05-28","conditions":"Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT06288191","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-06-21","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05134948","phase":"PHASE1, PHASE2","title":"A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-11-30","conditions":"Advanced Solid Tumors","enrollment":24},{"nctId":"NCT07223411","phase":"","title":"Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-11-19","conditions":"Locally Advanced Melanoma","enrollment":20},{"nctId":"NCT07091695","phase":"","title":"Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-11","conditions":"Melanoma","enrollment":100},{"nctId":"NCT02060188","phase":"PHASE2","title":"A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03-12","conditions":"Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer","enrollment":385},{"nctId":"NCT04866810","phase":"NA","title":"The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-25","conditions":"Melanoma","enrollment":24},{"nctId":"NCT04935229","phase":"PHASE1","title":"Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma","status":"TERMINATED","sponsor":"TriSalus Life Sciences, Inc.","startDate":"2021-08-02","conditions":"Metastatic Uveal Melanoma in the Liver","enrollment":67},{"nctId":"NCT04623775","phase":"PHASE2","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-02-17","conditions":"Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":468},{"nctId":"NCT05704933","phase":"EARLY_PHASE1","title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-06-06","conditions":"Metastatic Melanoma, Metastasis to Brain","enrollment":1},{"nctId":"NCT04953104","phase":"PHASE2","title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-21","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":6},{"nctId":"NCT04095208","phase":"PHASE2","title":"Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Bergonié","startDate":"2020-02-27","conditions":"Soft Tissue Sarcoma Adult, Advanced Cancer","enrollment":67},{"nctId":"NCT05148546","phase":"PHASE2","title":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2022-04-28","conditions":"Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT06880198","phase":"NA","title":"Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma","status":"RECRUITING","sponsor":"Fondazione Melanoma Onlus","startDate":"2024-08-01","conditions":"Melanoma Metastatic, Locally Advanced Melanoma","enrollment":20},{"nctId":"NCT05629546","phase":"PHASE1","title":"Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-06","conditions":"Advanced Melanoma, Metastatic Melanoma","enrollment":33},{"nctId":"NCT06624644","phase":"PHASE2, PHASE3","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","status":"RECRUITING","sponsor":"Linnaeus Therapeutics, Inc.","startDate":"2025-08-06","conditions":"Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma","enrollment":135},{"nctId":"NCT03470922","phase":"PHASE2, PHASE3","title":"A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-04-11","conditions":"Melanoma","enrollment":714},{"nctId":"NCT06712927","phase":"PHASE2","title":"Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-08-06","conditions":"Melanoma, Brain Metastases","enrollment":60},{"nctId":"NCT06237920","phase":"PHASE2","title":"Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-02-19","conditions":"Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site","enrollment":90},{"nctId":"NCT05625399","phase":"PHASE3","title":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-03-06","conditions":"Melanoma","enrollment":579},{"nctId":"NCT05328908","phase":"PHASE3","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-04-28","conditions":"Colorectal Neoplasms","enrollment":770},{"nctId":"NCT04611126","phase":"PHASE1, PHASE2","title":"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer","status":"TERMINATED","sponsor":"Inge Marie Svane","startDate":"2021-04-22","conditions":"Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer","enrollment":6},{"nctId":"NCT07079644","phase":"","title":"Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-29","conditions":"Advanced Melanoma","enrollment":678},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03642067","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-02-12","conditions":"Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma","enrollment":59},{"nctId":"NCT06101134","phase":"PHASE2","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-11-06","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03459222","phase":"PHASE1, PHASE2","title":"An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-30","conditions":"Advanced Cancer","enrollment":229},{"nctId":"NCT02966548","phase":"PHASE1","title":"Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-04","conditions":"Cancer","enrollment":35},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":"Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction","enrollment":274},{"nctId":"NCT06683755","phase":"PHASE1, PHASE2","title":"Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-05-01","conditions":"Melanoma","enrollment":30},{"nctId":"NCT03743766","phase":"PHASE2","title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","status":"COMPLETED","sponsor":"John Kirkwood","startDate":"2019-03-29","conditions":"Melanoma","enrollment":42},{"nctId":"NCT03493932","phase":"PHASE1","title":"Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-24","conditions":"Glioblastoma","enrollment":21},{"nctId":"NCT03867799","phase":"PHASE2","title":"iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2019-03-27","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT04205552","phase":"PHASE2","title":"Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"University Hospital, Essen","startDate":"2020-03-04","conditions":"NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I","enrollment":90},{"nctId":"NCT06400264","phase":"PHASE2","title":"Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-22","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":""},{"nctId":"NCT04204837","phase":"PHASE2","title":"Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","status":"RECRUITING","sponsor":"Salzburger Landeskliniken","startDate":"2017-03-06","conditions":"Squamous Cell Carcinoma of the Skin","enrollment":61},{"nctId":"NCT03623854","phase":"PHASE2","title":"Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-03","conditions":"Chordoma, Locally Advanced Chordoma, Metastatic Chordoma","enrollment":10},{"nctId":"NCT02519322","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-02-02","conditions":"Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma","enrollment":53},{"nctId":"NCT03310619","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-20","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":62},{"nctId":"NCT04062656","phase":"PHASE2","title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2019-09-26","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":21},{"nctId":"NCT05934214","phase":"","title":"EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2023-01-01","conditions":"Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis","enrollment":141630},{"nctId":"NCT05498480","phase":"PHASE1","title":"Study of Relatlimab in Combination With Nivolumab in Chinese Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-07-27","conditions":"Advanced Solid Tumors","enrollment":6},{"nctId":"NCT02488759","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-13","conditions":"Various Advanced Cancer","enrollment":578},{"nctId":"NCT02935634","phase":"PHASE2","title":"A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-29","conditions":"Advanced Gastric Cancer","enrollment":190},{"nctId":"NCT04112498","phase":"PHASE1","title":"A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-10-01","conditions":"Cancer","enrollment":24},{"nctId":"NCT02061761","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03-13","conditions":"Hematologic Neoplasms","enrollment":106},{"nctId":"NCT02996110","phase":"PHASE2","title":"A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-02-02","conditions":"Advanced Cancer","enrollment":182},{"nctId":"NCT05077280","phase":"PHASE2","title":"A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"California Pacific Medical Center Research Institute","startDate":"2021-09-20","conditions":"Uveal Melanoma","enrollment":40},{"nctId":"NCT04913922","phase":"PHASE2","title":"Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML","status":"RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-05-05","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03335540","phase":"PHASE1","title":"An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-07","conditions":"Advanced Cancer","enrollment":20},{"nctId":"NCT05170685","phase":"","title":"Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"","enrollment":""},{"nctId":"NCT03724968","phase":"PHASE2","title":"Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression","status":"TERMINATED","sponsor":"Elizabeth Davis","startDate":"2019-01-17","conditions":"Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression","enrollment":2},{"nctId":"NCT02750514","phase":"PHASE2","title":"An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05-09","conditions":"Advanced Cancer","enrollment":295}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Opdualag","OPDUALAG","Relopduo","BMS-986213"],"phase":"marketed","status":"active","brandName":"Nivolumab + Relatlimab","genericName":"Nivolumab + Relatlimab","companyName":"H. Lee Moffitt Cancer Center and Research Institute","companyId":"h-lee-moffitt-cancer-center-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab and relatlimab together block two immune checkpoint pathways (PD-1 and LAG-3) to enhance anti-tumor T-cell activity. Used for Melanoma (unresectable or metastatic), Melanoma (adjuvant treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}